Annual report [Section 13 and 15(d), not S-K Item 405]

Document and Entity Information

v3.26.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Mar. 20, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Trading Symbol IKT    
Entity Registrant Name INHIBIKASE THERAPEUTICS, INC.    
Entity Central Index Key 0001750149    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Emerging Growth Company false    
Entity Small Business true    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   132,032,636  
Entity Public Float     $ 127.3
Entity Tax Identification Number 26-3407249    
Entity Interactive Data Current Yes    
Document Annual Report true    
Document Transition Report false    
Security Exchange Name NASDAQ    
Documents Incorporated by Reference

None

    
Entity Address, Address Line One 1000    
Entity Address, Address Line Two Suite 1200    
Entity Address, City or Town Wilmington    
Entity Address, State or Province DE    
Entity Address, Postal Zip Code 19801    
City Area Code (302    
Local Phone Number 295-3800    
Entity Incorporation, State or Country Code DE    
Title of 12(b) Security Common Stock, $0.001 par value    
Entity File Number 001-39676    
Auditor Name CohnReznick LLP    
Auditor Firm ID 596    
Auditor Location Holmdel, New Jersey    
Document Financial Statement Error Correction [Flag] false    
Auditor Opinion

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Inhibikase Therapeutics, Inc. and Subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.